KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 79 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.13 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $50 | -61.2% | 27,840 | -15.8% | 0.00% | -100.0% |
| Q1 2023 | $129 | +33.0% | 33,054 | +15.6% | 0.00% | 0.0% |
| Q4 2022 | $97 | -99.9% | 28,597 | +22.4% | 0.00% | 0.0% |
| Q3 2022 | $128,000 | +161.2% | 23,373 | +115.3% | 0.00% | – |
| Q2 2022 | $49,000 | -52.4% | 10,857 | -22.3% | 0.00% | -100.0% |
| Q1 2022 | $103,000 | +22.6% | 13,977 | +6.6% | 0.00% | – |
| Q4 2021 | $84,000 | -27.0% | 13,107 | +9.0% | 0.00% | -100.0% |
| Q4 2017 | $115,000 | +475.0% | 12,030 | +300.2% | 0.00% | – |
| Q2 2016 | $20,000 | -4.8% | 3,006 | +24.8% | 0.00% | – |
| Q1 2016 | $21,000 | -16.0% | 2,408 | +29.3% | 0.00% | – |
| Q4 2015 | $25,000 | 0.0% | 1,863 | -22.7% | 0.00% | – |
| Q3 2015 | $25,000 | +19.0% | 2,411 | +216.0% | 0.00% | – |
| Q2 2015 | $21,000 | +16.7% | 763 | +28.5% | 0.00% | – |
| Q1 2015 | $18,000 | +12.5% | 594 | +37.8% | 0.00% | – |
| Q4 2014 | $16,000 | -15.8% | 431 | -21.6% | 0.00% | – |
| Q3 2014 | $19,000 | +46.2% | 550 | +95.7% | 0.00% | – |
| Q2 2014 | $13,000 | – | 281 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,200,396 | $30,084,000 | 1.72% |
| TFS CAPITAL LLC | 105,040 | $987,000 | 0.26% |
| Tekla Capital Management LLC | 500,324 | $4,703,000 | 0.20% |
| Piermont Capital Management Inc. | 51,080 | $480,000 | 0.11% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 55,793 | $524,000 | 0.09% |
| Candriam S.C.A. | 390,000 | $3,666,000 | 0.08% |
| Virtus ETF Advisers LLC | 27,446 | $258,000 | 0.08% |
| SECOR Capital Advisors, LP | 66,484 | $625,000 | 0.08% |
| Trexquant Investment LP | 29,007 | $273,000 | 0.04% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 32,196 | $303,000 | 0.04% |